Valuation Protalix BioTherapeutics, Inc. TEL AVIV STOCK EXCHANGE
Stocks
PLX
US74365A3095
Pharmaceuticals
|
Delayed
TEL AVIV STOCK EXCHANGE
15:24:48 21/03/2023 GMT
|
5-day change | 1st Jan Change | ||
| 732.50 ILa | -.--% |
|
+3.29% | +69.68% |
| 08-12 | Protalix BioTherapeutics, Inc., Q2 2026 Earnings Call, Aug 12, 2026 | |
| 08-12 | Protalix BioTherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Company Valuation: Protalix BioTherapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 37.89 | 69.41 | 129.9 | 138.4 | 144.8 | 215.1 | - | - |
| Change | - | 83.2% | 87.08% | 6.6% | 4.57% | 48.61% | - | - |
| Enterprise Value (EV) | 37.89 | 69.41 | 129.9 | 138.4 | 144.8 | 215.1 | 215.1 | 215.1 |
| Change | - | 83.2% | 87.08% | 6.6% | 4.57% | 48.61% | 0% | 0% |
| P/E | -1.34x | -4.42x | 19.8x | 47x | -22.5x | 11.1x | 53.4x | 134x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0.1x | -0x | -0.8x | 0x | -0x | -0.7x | -2.2x |
| Capitalization / Revenue | 0.99x | 1.46x | 1.98x | 2.59x | 2.74x | 2.62x | 3.24x | 3.13x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 2.62x | 3.24x | 3.13x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | 0x | 0x | -0x | 9.52x | 83.1x | 190x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.62 | -0.31 | 0.09 | 0.04 | -0.08 | 0.24 | 0.05 | 0.02 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 38.35 | 47.64 | 65.49 | 53.4 | 52.74 | 82.16 | 66.48 | 68.82 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -20.46 | -13.01 | 10.46 | 3.917 | -5.5 | 22.59 | 2.588 | 1.131 |
| Net income 1 | -27.58 | -14.93 | 8.312 | 2.932 | -6.604 | 19.63 | 3.794 | 1.518 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 0.832 | 1.370 | 1.780 | 1.880 | 1.800 | 2.670 | 2.670 | 2.670 |
| Nbr of stocks (in thousands) | 45,557 | 50,666 | 72,952 | 73,634 | 80,421 | 80,572 | - | - |
| Announcement Date | 31/03/22 | 27/02/23 | 14/03/24 | 17/03/25 | 18/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 32x | 11.63x | 23.59x | 0.62% | 1,002B | |
| 28.37x | 6.53x | 17.91x | 2.01% | 644B | |
| 32.13x | 7.46x | 15.49x | 2.73% | 443B | |
| 18.9x | 4.61x | 11.42x | 2.88% | 343B | |
| 19.46x | 5.11x | 12.69x | 3.2% | 262B | |
| 20.29x | 4.17x | 11.93x | 2.12% | 245B | |
| 24.75x | 6.5x | 11.57x | 2.58% | 212B | |
| 12.86x | 4.67x | 9.75x | 3.91% | 199B | |
| -44.5x | 6.43x | 25.11x | 2.26% | 181B | |
| Average | 16.03x | 6.35x | 15.50x | 2.48% | 392.19B | |
| Weighted average by Cap. | 22.91x | 7.53x | 17.31x | 2.04% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- PLX Stock
- PLX Stock
- Valuation Protalix BioTherapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
